Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes

International Journal of Antimicrobial Agents

Volumn 45, Issue 6, 2015, Pages 605-609

  Kwon, Ki Hwan ^a   Oh, Jin Young ^a   Yoon, Young Soon ^a   Jeong, Yun Jeong ^a   Kim, Kyung Soo ^b   Shin, Sung Joon ^b   Chung, Jae Woo ^a   Huh, Hee Jin ^a   Chae, Seok Lae ^a   Park, Seong Yeon ^b  

^a Dongguk University   (South Korea)

^b Dongguk University Ilsan Hospital   (South Korea)

Author keywords

Carbapenem resistant Acinetobacter baumannii; Colistimethate sodium; Nephrotoxicity; Pneumonia

Indexed keywords

ANTIINFECTIVE AGENT; COLISTIN; COLISTINMETHANESULFONIC ACID;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; RENAL INSUFFICIENCY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADMINISTRATION, INTRAVENOUS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; COLISTIN; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84940001276     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.01.011     Document Type: Article

References (30)

1. A. Michalopoulos, and M.E. Falagas Colistin and polymyxin B in critical care Crit Care Clin 24 2008 377 391
2. J.M. Pogue, J. Lee, D. Marchaim, V. Yee, J.J. Zhao, T. Chopra, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system Clin Infect Dis 53 2011 879 884
3. J.D. Hartzell, R. Neff, J. Ake, R. Howard, S. Olson, K. Paolino, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center Clin Infect Dis 48 2009 1724 1728
4. F.F. Tuon, M.H. Rigatto, C.K. Lopes, L.K. Kamei, J.L. Rocha, and A.P. Zavascki Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium Int J Antimicrob Agents 43 2014 349 352
5. C.A. DeRyke, A.J. Crawford, N. Uddin, and M.R. Wallace Colistin dosing and nephrotoxicity in a large community teaching hospital Antimicrob Agents Chemother 54 2010 4503 4505
6. M. Rocco, L. Montini, E. Alessandri, M. Venditti, A. Laderchi, G. De Pascale, et al. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study Crit Care 17 2013 R174
7. M.E. Falagas, M. Rizos, I.A. Bliziotis, K. Rellos, S.K. Kasiakou, and A. Michalopoulos Toxicity after prolonged (more than four weeks) administration of intravenous colistin BMC Infect Dis 5 2005 1
8. R.A. Weinstein, R. Gaynes, and J.R. Edwards Overview of nosocomial infections caused by Gram-negative bacilli Clin Infect Dis 41 2005 848 854
9. T. Kim, Y.P. Chong, S.Y. Park, M.-H. Jeon, E.J. Choo, J.-W. Chung, et al. Risk factors for hospital-acquired pneumonia caused by carbapenem-resistant Gram-negative bacteria in critically ill patients: a multicenter study in Korea Diagn Microbiol Infect Dis 78 2014 457 461
10. J. Garnacho-Montero, C. Ortiz-Leyba, F.J. Jiménez-Jiménez, A.E. Barrero-Almodóvar, J.L. García-Garmendia, M. Bernabeu-WittelI, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP Clin Infect Dis 36 2003 1111 1118
11. R. Bellomo, C. Ronco, J.A. Kellum, R.L. Mehta, and P. Palevsky Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group Crit Care 8 2004 R204
12. M.E. Charlson, F.L. Sax, C.R. Mackenzie, R.L. Braham, S.D. Fields, and R. Douglas Jr. Morbidity during hospitalization: can we predict it? J Chronic Dis 40 1987 705 712
13. W.A. Knaus, E.A. Draper, D.P. Wagner, and J.E. Zimmerman APACHE II: a severity of disease classification system Crit Care Med 13 1985 818 829
14. A.S. Levey, L.A. Stevenes, C.H. Schmid, Y.L. Zhang, A.F. Castro, H.I. Feldman, et al. A new equation to estimate glomerular filtration rate Ann Intern Med 60 2009 4 12
15. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2002 S1 S266
16. S.-H. Kim, S.-B. Hong, S.-C. Yun, W.-I. Choi, J.-J. Ahn, Y.-J. Lee, et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection Am J Respir Crit Care Med 183 2011 1207 1214
17. M.E. Evans, D.J. Feola, and R.P. Rapp Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria Ann Pharmacother 33 1999 960 967
18. Clinical Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. Document M100-S21 2011 CLSI Wayne, PA
19. G. Vicari, S.R. Bauer, E.A. Neuner, and S.W. Lam Association between colistin dose and microbiologic outcomes in patient with multidrug-resistant Gram-negative bacteremia Clin Infect Dis 56 2013 398 404
20. M.E. Falagas, P.I. Rafailidis, E. Ioannidou, V.G. Alexiou, D.K. Matthaiou, D.E. Karageorgopoulos, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients Int J Antimicrob Agents 35 2010 194 199
21. W. Couet, N. Grégoire, S. Marchand, and O. Mimoz Colistin pharmacokinetics: the fog is lifting Clin Microbiol Infect 18 2012 30 39
22. S.M. Garonzik, J. Li, V. Thamlikitkul, D.L. Paterson, S. Shoham, J. Jacob, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients Antimicrob Agents Chemother 55 2011 3284 3294
23. N.H. Lameire, A. Bagga, D. Cruz, J. De Maeseneer, Z. Endre, J.A. Kellum, et al. Acute kidney injury: an increasing global concern Lancet 382 2013 170 179
24. R.B. Hines, C. Chatla, H.L. Bumpers, J.W. Waterbor, G. McGwin, E. Funkhouser, et al. Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer J Clin Oncol 27 2009 4339 4345
25. T. Ali, I. Khan, W. Simpson, G. Prescott, J. Townend, W. Smith, et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study J Am Soc Nephrol 18 2007 1292 1298
26. V.G. Portella, J.L. Silva-Filho, S.S. Landgraf, T.B. de Rico, M.A.R. Vieira, C.M. Takiya, et al. Sepsis-surviving mice are more susceptible to a secondary kidney insult Crit Care Med 41 2013 1056 1068
27. S.M. Bagshaw, S. Lapinsky, S. Dial, Y. Arabi, P. Dodek, G. Wood, et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy Intensive Care Med 35 2009 871 881
28. M. Turkoglu, M. Dizbay, A. Ciftçi, F.N. Aksakal, and G. Aygencel Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction Int J Antimicrob Agents 39 2012 142 145
29. C.L. Sprung, D. Annane, D. Keh, R. Moreno, M. Singer, K. Freivogel, et al. CORTICUS Study Group Hydrocortisone therapy for patients with septic shock N Engl J Med 358 2008 111 124
30. D. Annane, V. Sébille, C. Charpentier, P.E. Bollaert, B. François, J.M. Korach, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock JAMA 288 2002 862 871